Login to Your Account



Clinic Roundup


Wednesday, March 16, 2011
Oxford BioMedica plc, of Oxford, UK, reported further analyses from its Phase III trial of cancer vaccine TroVax showed that, when applying the immune response surrogate (IRS) algorithm for predicting quantitative 5T4 antibody response, a significant correlation was seen between the antibody response induced following TroVax vaccination and treatment benefit. Patients with higher IRS values treated with TroVax survived longer than patients in the placebo group with the same IRS values. IRS also was associated with 5T4 antibody response and survival when applied to an independent dataset derived from the nine previous Phase I and Phase II studies of TroVax in patients with renal, colorectal and prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription